Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Material AgreementItem 1.01 · 8-KLOW RiskPositive

FOXO TECHNOLOGIES INC.

foxotechnologies.com
Filed: May 27, 2026Minneapolis, MinnesotaCIK: 0001812360Health Care
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

FOXO Technologies entered into a Strategic Technology License Agreement with Jon R. Sabes and LongevityFP Technologies, LLC on May 27, 2026, granting an exclusive worldwide license to commercialize FOXO's epigenetics intellectual property portfolio including two U.S. patents and a dataset of over 13,000 epigenetic data points. This represents a significant commercialization expansion for FOXO's biotech intellectual property.

Key Takeaways

FOXO granted LongevityFP an exclusive, worldwide license to commercialize its epigenetics IP portfolio, including U.S. Patent Nos. 11,795,495 and 11,817,214

The agreement includes access to a proprietary dataset containing over 13,000 epigenetic data points and proprietary machine learning technologies

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMay 27, 2026
Item1.01
CategoryMaterial Agreement
CIK0001812360
Accession #001-39783
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
material agreementpartnership

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings